Goldman Sachs initiates Royalty Pharma stock with Buy rating, $42 target
PositiveFinancial Markets

Goldman Sachs has initiated coverage of Royalty Pharma with a 'Buy' rating and set a target price of $42 per share. This positive outlook reflects confidence in Royalty Pharma's business model and growth potential, making it an attractive option for investors looking for opportunities in the pharmaceutical sector.
— Curated by the World Pulse Now AI Editorial System